Chronotherapy

Property	Information
Drug Name	Chronotherapy with Temozolomide (TMZ)
FDA Approval	Yes (as part of standard glioblastoma treatment)
Used for	Glioblastoma Multiforme (GBM)
Clinical Trial Phase	Research ongoing
Clinical Trial Explanation	Not specified
Common Side Effects	Increased side effects when administered in the morning; however, these are generally manageable with other therapies.
OS without	Around 19.5 months for patients with MGMT methylated tumors.
OS with	Up to 17 months for general cases, and up to 25.5 months for patients with MGMT methylated tumors when administered in the morning.
PFS without	Standard progression statistics for GBM.
PFS with	Improved in morning dosing, exact data still under investigation.
Usefulness Rating	4
Usefulness Explanation	Chronotherapy with TMZ could significantly extend survival times, particularly for patients with MGMT methylated tumors.
Toxicity Level	Comparable to standard TMZ treatments, but timing affects management of side effects.
Toxicity Explanation	Morning administration of TMZ shows potential for increased efficacy, with manageable increases in side effects.

Notes: Emerging evidence suggests that adjusting the timing of TMZ to morning administration could extend overall survival times for GBM patients, particularly those with MGMT methylated tumors. This approach aligns with the chronotherapy concept, which utilizes the body's circadian rhythms to optimize drug efficacy and minimize toxicity.

Links: https://medicine.wustl.edu/news/chemo-for-glioblastoma-may-work-better-in-morning-than-evening/, https://www.mdpi.com/2072-6694/13/11/2659

From Ben Williams Book: Not specified

Loading comments...